Hofseth BioCare ASA (OSL: HBC)
Norway
· Delayed Price · Currency is NOK | Market Cap | 830.38M |
| Revenue (ttm) | 230.08M |
| Net Income (ttm) | -121.18M |
| Shares Out | 411.08M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,785 |
| Open | 1.850 |
| Previous Close | 2.050 |
| Day's Range | 1.850 - 2.040 |
| 52-Week Range | 1.800 - 3.280 |
| Beta | 0.37 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 29, 2024 |
About Hofseth BioCare ASA
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company’s products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism, and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was incorporated in 200... [Read more]
Financial Performance
In 2023, HBC's revenue was 218.51 million, an increase of 81.42% compared to the previous year's 120.45 million. Losses were -106.68 million, -22.35% less than in 2022.
Financial StatementsNews
Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT
HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year. Adjusted for the sale of assets in the second quarter, sales revenues were NOK 72...
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China.
Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT
The first quarter of 2024 continued on the positive trend for HBC. Sales revenues came in at NOK 52m vs NOK 44m last year, a growth of 17 % YoY. The underlying growth we are seeing is coming from both...
Hofseth Biocare ASA: THIRD QUARTER 2023 FINANCIAL REPORT
The third quarter of 2023 shows a significant growth of forty percent in sales compared to the same period last year and the increase in margins in Q2 continues. Sales revenues ended at NOK 49.9m vs N...
Hofseth Biocare ASA: FOURTH QUARTER 2022 & FULL YEAR FINANCIAL REPORT
In Q4, the ingredients business continued to show favorable momentum with growth of 87 %, compared to same quarter last year on an underlying basis, generating sales revenues of NOK 34m, compared to N...
Hofseth Biocare ASA: HOFSETH BIOCARE AWARDED BEST SUSTAINABLE BIOTECH COMPANY 2022 ACCOLADE
Hofseth BioCare (HBC) has been named Best Sustainable Biotech Company 2022 in the Global Health & Pharma Biotechnology Awards. The award is in recognition of HBC's 15 years of pioneering research and ...
Hofseth Biocare ASA: GLOBAL INNOVATION PARTNERSHIP WITH CATALENT TO DEVELOP DELAYED-RELEASE FORMULATION OF OMEGO FISH OIL
ÅLESUND, NORWAY – May 12, 2021 — Hofseth BioCare ASA (HBC), a Norwegian biotech company that develops high-value ingredients and finished products, today announced that it has begun a global innovatio...
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA (“HBC”), has today purchased 70,000 shares in HBC at an average price of NOK 9.294 per share.
Hofseth Biocare ASA: FOURTH QUARTER 2020 FINANCIAL REPORT
HBC had gross operating revenues of NOK 69.3m (67.8m) in 2020 and operating revenues of NOK 23.1m (11.1m) in the fourth quarter. Cost of Goods Sold (CoGS) amounted to NOK 16.7m (16.6m) in the quarter ...
Hofseth Biocare ASA: TOP TIER RECRUITMENT TO FURTHER STRENGTHEN FOCUS ON SALES AND MARKETING
Hofseth Biocare ASA (HBC) is delighted to announce the hiring of Reto Renggli as VP within HBC's Consumer Health Division as of February 1st 2021.The new addition to the team is the last in a series o...
Hofseth Biocare ASA: Boosts Sales & Marketing in its Consumer Health division by hiring ex-Novartis and ex-GSK senior executive Andy Gill
HBC is delighted to announce the hiring of Andy Gill as VP within HBC's Consumer Health Division from January 2021. Mr Gill is a highly accomplished commercial leader with over 20 years' experience in...